AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 82 min read$NUVL

Porter James Richard sold $3.7M of NUVL

Porter James Richard (President and CEO) sold 30,000 shares of Nuvalent, Inc. (NUVL) at $123.72 ($3.71M total) on 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Porter James Richard
Published Jul 8, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 8, 2026, 8:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NUVL
Neutral
high confidence
Mentioned
$NUVL
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NUVLNeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale size and price, but the presence of a pre-arranged 10b5-1 plan reduces interpretive weight.

02

Market read

Primarily a sentiment/positioning datapoint for NUVL, with low expected fundamental impact.

03

What to watch

Insider sales under 10b5-1 plans often have limited interpretive value; traders should focus on any concurrent company-specific catalysts not present in this filing.

Relevance 5/10Novelty 3/10Timing: Filed 2026-07-08 after-hours, reflecting a 2026-07-06 sale.

Background

The article is an SEC Form 4 insider transaction disclosure for Nuvalent, Inc. (NUVL).

Company-level read

Ticker impact

$NUVLNeutralHigh confidence
Context

Nuvalent CEO Porter James Richard sold 30,000 shares on 2026-07-06 at $123.72, totaling $3.71M, under a 10b5-1 plan.

Expected impact

Limited near-term impact; any reaction is likely sentiment-driven and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction with an explicitly pre-arranged 10b5-1 plan, and it does not include new operating, regulatory, or financial guidance.

Market effects

Sector

No clear sector read-across from a single 10b5-1 insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be purely planned liquidity, so it should not be treated as a bearish signal about Nuvalent fundamentals.

Key entities

  • issuer
    Nuvalent, Inc.

    Company whose CEO filed the Form 4 insider sale disclosure.

  • insider
    Porter James Richard

    President and CEO who sold 30,000 shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NUVL insider trading history →

Related articles

JUL 15
$GSKMedAI 8/10

GSK completes acquisition of Nuvalent, Inc

GSK said it has completed its acquisition of Nuvalent (NASDAQ: NUVL) via a tender offer. The deal adds three lung cancer assets, including zidesamtinib (NVL-520) and neladalkib (NVL-655) under FDA review, plus NVL-330 in phase I. Transaction value is about $10.6B (£8.0B), net investment about $9.4B (£7.1B).

investegate.co.uk4 min
JUN 10
$MRVLMed

Stocks Erase Early Gains as Chipmakers Turn Lower

US stocks pared early gains as chipmakers and software firms fell. Marvell, Qualcomm, ARM and others dropped, while ServiceNow and Salesforce also declined. Treasury yields were pressured by a $58B 3-year auction and stronger May existing home sales. In Europe, Bund and gilt yields fell; swaps price a 100% chance of a 25 bp ECB hike. UNFI slid after Q3 sales missed; Nuvalent surged on a $10.6B GSK buyout.

finance.yahoo.com7 min
JUN 9
$MUMed

More swings for AI stocks drag Wall Street back on the roller coaster

Wall Street swung as AI-related chip and memory stocks reversed after early gains. The S&P 500 fell 0.3% (7,386.65), the Nasdaq dropped 1% (25,678.82), and the Dow rose 0.2% (50,872.11). Micron slid 1.4% after a 10% drop; it had surged 9.9% Monday. Oil eased (Brent -3% to $91.45) but AI weakness outweighed. GSK agreed to buy Nuvalent for $10.6B, sending Nuvalent up 39.3%.

latimes.com6 min
JUN 9
$COHRMed

Benzinga

U.S. stocks fell Tuesday as rotation out of chip and AI leaders resumed: Nasdaq 100 -3.3% to ~28,437, S&P 500 -1.6% to ~7,228, Dow -0.5% to ~50,535. Oil dropped ~6% and markets priced ~50% odds of a Fed hike by October ahead of Wednesday’s CPI. Tech led declines (XLK -5.1%); SMH fell as COHR -15.2%, MRVL -12.1%, LITE -11.8%.

benzinga.com7 min
JUN 9
$GSKHighAI 9/10

GSK Strikes $10.6B Nuvalent Deal Strengthening Targeting Cancer Pipeline

GSK agreed to acquire Nuvalent for $10.6B (£8.0B) to strengthen its late-stage oncology pipeline. GSK will tender for all Nuvalent shares at $124 cash, a 40% premium; net investment is $9.4B. Nuvalent’s FDA-review candidates Zidesamtinib and Neladalkib have 2026 decision dates. Deal expected to close in Q3 2026; GSK said 2026 outlook and 70p dividend remain unchanged.

rttnews.com6 min
JUN 9
$GSKHighAI 9/10

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10. 6 Billion For Cancer Drug Developer Nuvalent

GSK will acquire Nuvalent for $10.6 billion, buying all outstanding shares for $124 cash each, a 40% premium to Nuvalent’s last close of $88.49. Nuvalent shares rose about 39% in premarket. GSK expects revenue growth and accretion to sales and core operating profit from 2027, and higher core EPS from 2029, gaining lung cancer assets including zidesamtinib and neladalkib.

benzinga.com4 min